Evidence map›Paper›PMID 30537941›Full record

ArticleBMC cancer2018

SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma.

Yibing Chen, Jingjing Zhao, Zhihui Jiao, Weiwei Wang, Dandan Wang, Xiaohe Yu, Zhiyong Shi, Naijian Ge, Qiuzhong Pan, Jianchuan Xia and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Yibing ChenGenetic and Prenatal Diagnosis Center, Department of Gynecology and Obstetrics, First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, Henan, China.
Jingjing ZhaoState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China.
Zhihui JiaoGenetic and Prenatal Diagnosis Center, Department of Gynecology and Obstetrics, First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, Henan, China.
Weiwei WangDepartment of Pathology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, Henan, China.
Dandan WangKey Laboratory for Biotech-Drugs Ministry of Health, Key Laboratory for Modern Medicine and Technology of Shandong Province, Key Laboratory for Rare & Uncommon Diseases of Shandong Province, Back and Neck Pain Hospital, Shandong Academy of Medical Sciences, Jinan, 250062, Shandong, China.
Xiaohe YuDepartment of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Zhiyong ShiDepartment of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Naijian GeDepartment of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.
Qiuzhong PanState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China.
Jianchuan XiaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China.
Wancheng NiuDepartment of General Surgery, Huaihai Hospital, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Ruihua ZhaoDepartment of Medical Oncology, First Affiliated Hospital, Zhengzhou University, 1 Jianshe Road East, Zhengzhou, 450052, Henan, China.
Xiaofei ZhangDepartment of Medical Oncology, First Affiliated Hospital, Zhengzhou University, 1 Jianshe Road East, Zhengzhou, 450052, Henan, China. zhangxiaoxiaofeifie@foxmail.com.
Wei DuDepartment of Neurosurgery, First Affiliated Hospital, Zhengzhou University, 1 Jianshe Road East, Zhengzhou, 450052, Henan, China. duwei@zzu.edu.cn.
First Affiliated Hospital of Zhengzhou University · CNSecond Military Medical University · CNSun Yat-sen University · CNEastern Hepatobiliary Surgery Hospital · CNShandong First Medical University · CNSun Yat-sen University Cancer Center · CNXuzhou Medical College · CN

Funding

Henan Medical Program 201602072Henan Science & Technology Program 172102310271National Natural Science Foundation of China (81402560
6 · The paper itself

Abstract

backgroundSKA1, an important mitosis protein, has been indicated in the initiation and progression of several malignancies. However, its clinical significance in hepatocellular carcinoma (HCC) remain to be elucidated.

methodsmRNA expression of SKA1 was examined in 126 HCC and paired non-neoplastic tissues using real-time PCR and validated in The Cancer Genome Atlas (TCGA) database. SKA1 protein expression was detected using immunohistochemistry in the 126 HCC tissues and its associations with clinicopathological parameters and prognosis were analyzed. Hierarchical cluster analysis and gene set enrichment analysis (GSEA) were performed in selected Gene Expression Omnibus data sets.

resultsSKA1 mRNA expression was significantly elevated in HCC tissues from both local hospital and TCGA database. Immunohistochemistry revealed that increased SKA1 expression was present in 65 of the 126 cases and was significantly associated with higher serum alpha-fetoprotein concentration, larger tumor size and higher TNM stage. Patients with positive SKA1 expression showed significantly worse overall and relapse-free survival. Multivariate Cox regression analysis revealed that SKA1 was an independent predictor of patient prognosis. Gene expression profiling analysis of public data showed that high-SKA1 expression HCC tissues had similar gene expression profiles with fetal liver tissues. Moreover, GSEA showed that genes up-regulated in high SKA1 HCC subgroup were significantly enriched in cell cycle pathway, while genes down-regulated were significantly enriched in apoptosis pathway.

conclusionsOur findings indicate that the oncofetal gene SKA1 might be involved in the progression of the HCC and could serve as a prognostic marker for HCC.

Indexed as

ApoptosisCarcinoma, HepatocellularChromosomal Proteins, Non-HistoneDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiddle AgedPrognosisRNA, MessengerUp-RegulationChromosomal Proteins, Non-HistoneRNA, MessengerSKA1 protein, humanGene profilingHepatocellular carcinomaOncofetal genePrognosisSKA1

Identifiers

PMID30537941
PMCPMC6288885
OpenAlexW2903776113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.